FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Stem Cell Treatment Looks Promising for MS











































Image Source: KRESTAINTHEAFTERNOON

A recent study describes the first treatment that completely halts all detectable inflammatory activity in the central nervous system (CNS) in patients diagnosed with multiple sclerosis (MS), for a prolonged period and without the use of disease modifying drugs. The study, published in The Lancet online on June 9, 2016, was conducted by Harold Atkins, MD, of the Ottawa Hospital Research Institute in Ottawa, Canada.

This was a phase 2, single-arm trial, involving patients diagnosed with MS with a poor prognosis, across three hospitals in Canada. There were 24 participants between the ages of 18 and 50 years. The participants completed a transplant conditioning program, and then an autologous CD34 hemopoietic stem-cell graft was infused. Following the infusion, the participants were admitted into a stem-cell transplantation ward where they were assessed for treatment-related toxic effects.

The transplantations occurred between October, 2001 and December, 2009. “The primary outcome, multiple sclerosis activity free survival at 3 years after transplantation was 69.9%,” said the authors. They add, “The treatment abolished all clinical and radiological hallmarks of disease-related CNS inflammation, without the use of disease-modifying drugs, during the entire extended follow-up period.”

In addition to halting inflammation, the researchers report, “Many of our patients recovered substantially, indicating that repair mechanisms were still active and might have been suppressed by ongoing inflammations.” Despite the positive outcome of this study, the researchers urge caution, saying that experience in selecting the best candidates and specialized care is necessary for the best outcomes in autologous hemopoietic stem-cell transplantation.

Although this study involved a small cohort without a control group, the researchers conclude, “For a substantial number of patients whose disease was not well-controlled with disease-modifying drugs, this procedure led to neurological improvement and long-lasting remission free of ongoing treatment.”

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News